Congenital myasthenic syndrome with episodic apnoea (CMS-EA) is a rare but potentially treatable cause of apparent life-threatening events in infancy. The underlying mechanisms for sudden and recurrent episodes of respiratory arrest in these patients are unclear. Whilst CMS-EA is most commonly caused by mutations in CHAT, the list of associated genotypes is expanding.
We reviewed clinical information from 19 patients with CMS-EA, including patients with mutations in CHAT, SLC5A7 and RAPSN, and patients lacking a genetic diagnosis.
Lack of genetic diagnosis was more common in CMS-EA than in CMS without EA (56% n = 18, compared to 7% n = 97). Most patients manifested intermittent apnoea in the first 4 months of life (74%, n = 14). A degree of clinical improvement with medication was observed in most patients (74%, n = 14), but the majority of cases also showed a tendency towards complete remission of apnoeic events with age (mean age of resolution 2 years 5 months). Signs of impaired neuromuscular transmission were detected on neurophysiology studies in 79% (n = 15) of cases, but in six cases, this was only apparent following specific neurophysiological testing protocols (prolonged high-frequency stimulation).
A relatively large proportion of CMS-EA remains genetically undiagnosed, which suggests the existence of novel causative CMS genes which remain uncharacterised. In light of the potential for recurrent life-threatening apnoeas in early life and the positive response to therapy, early diagnostic consideration of CMS-EA is critical, but without specific neurophysiology tests, it may go overlooked.
Abicht A, Müller J, Lochmüller H (1993) Congenital myasthenic syndromes. In: Pagon RA, Adam MP, Ardinger HH et al (eds) GeneReviews( ®). University of Washington, Seattle
American Academy of Pediatrics (1987) National Institutes of Health Consensus Development Conference on Infantile Apnea and Home Monitoring Sept 29 to Oct 1, 1986. Pediatrics 79:292–299
Arens R, Gozal D, Williams JC et al (1993) Recurrent apparent life-threatening events during infancy: a manifestation of inborn errors of metabolism. J Pediatr 123:415–418. https://doi.org/10.1016/S0022-3476(05)81747-0 CrossRefPubMed
Aquilonius SM, Eckernås SA, Sundwall A (1975) Regional distribution of choline acetyltransferase in the human brain: changes in Huntington’s chorea. J Neurol Neurosurg Psychiatr 38:669–677 CrossRef
Mattila PM, Röyttä M, Lönnberg P et al (2001) Choline acetyltransferase activity and striatal dopamine receptors in Parkinson’s disease in relation to cognitive impairment. Acta Neuropathol (Berl) 102:160–166
Bauché S, O’Regan S, Azuma Y et al (2016) Impaired presynaptic high-affinity choline transporter causes a congenital myasthenic syndrome with episodic apnea. Am J Hum Genet. https://doi.org/10.1016/j.ajhg.2016.06.033 PubMedPubMedCentral
O’Grady GL, Verschuuren C, Yuen M et al (2016) Variants in SLC18A3, vesicular acetylcholine transporter, cause congenital myasthenic syndrome. Neurology. https://doi.org/10.1212/WNL.0000000000003179 PubMedPubMedCentral
Aran A, Segel R, Kaneshige K et al (2017) Vesicular acetylcholine transporter defect underlies devastating congenital myasthenia syndrome. Neurology 88:1021–1028. https://doi.org/10.1212/WNL.0000000000003720 CrossRefPubMed
Engel AG, Selcen D, Shen X-M et al (2016) Loss of MUNC13-1 function causes microcephaly, cortical hyperexcitability, and fatal myasthenia. Neurol Genet 2. https://doi.org/10.1212/NXG.0000000000000105
Shen X-M, Selcen D, Brengman J, Engel AG (2014) Mutant SNAP25B causes myasthenia, cortical hyperexcitability, ataxia, and intellectual disability. Neurology 83:2247–2255. https://doi.org/10.1212/WNL.0000000000001079 CrossRefPubMedPubMedCentral
Natera-de Benito D, Bestué M, Vilchez JJ et al (2016) Long-term follow-up in patients with congenital myasthenic syndrome due to RAPSN mutations. Neuromuscul Disord 26:153–159. https://doi.org/10.1016/j.nmd.2015.10.013 CrossRefPubMed
Ohno K, Wang H-L, Milone M et al (1996) Congenital myasthenic syndrome caused by decreased agonist binding affinity due to a mutation in the acetylcholine receptor ε subunit. Neuron 17:157–170. https://doi.org/10.1016/S0896-6273(00)80289-5 CrossRefPubMed
Webster R, Liu W-W, Chaouch A et al (2014) Fast-channel congenital myasthenic syndrome with a novel acetylcholine receptor mutation at the α–ε subunit interface. Neuromuscul Disord 24:143–147. https://doi.org/10.1016/j.nmd.2013.10.009 CrossRefPubMed
Barwick KES, Wright J, Al-Turki S et al (2012) Defective presynaptic choline transport underlies hereditary motor neuropathy. Am J Hum Genet 91:1103–1107. https://doi.org/10.1016/j.ajhg.2012.09.019 CrossRefPubMedPubMedCentral
Wargon I, Richard P, Kuntzer T, et al (2012) Long-term follow-up of patients with congenital myasthenic syndrome caused by COLQ mutations. Neuromuscul Disord 22:318–324. https://doi.org/10.1016/j.nmd.2011.09.002 CrossRefPubMed
Shen XM, Okuno T, Milone M, Otsuka K, Takahashi K, Komaki H, Giles E, Ohno K, Engel AG (2016) Mutations causing slow-channel myasthenia reveal that a valine ring in the channel pore of muscle AChR is optimized for stabilizing channel gating. Hum Mutat 37(10):1051–1059. https://doi.org/10.1002/humu.23043 CrossRefPubMedPubMedCentral
- Congenital myasthenic syndrome with episodic apnoea: clinical, neurophysiological and genetic features in the long-term follow-up of 19 patients
Roger G. Whittaker
- Springer Berlin Heidelberg
Neu im Fachgebiet Neurologie
Meistgelesene Bücher in der Neurologie
Mail Icon II